Abstract:There is a lack of consistent guidelines and consensus for the diagnosis of laryngopharyngeal refl ux (LPR). A therapeutic trial with a proton pump inhibitor (PPI) has been suggested to identify patients with LPR. This review focuses on the current diffi culties in diagnosing the disease and examines the evidence for the effectiveness of PPI therapy in suspected refl ux-related laryngeal symptoms. Additionally, mode of action, safety, and tolerability of PPIs are described. A total of 7 placebo-controlled trials were identifi ed and included in the review. All studies evaluated the effect of a PPI on symptoms and objective laryngoscopic fi ndings in suspected LPR. Data from these trials show that PPI therapy is no more effective than placebo in producing symptom relief in patients suspected of LPR. Symptoms, laryngoscopic fi ndings, or abnormal fi ndings on pH monitoring will not predict response to PPI therapy. High placebo response levels suggest a much more complex and multifactorial pathophysiology of LPR than simple acid refl ux. Further studies are needed to characterize subgroups of patients with refl ux-associated laryngeal symptoms that might benefi t from treatment with PPI. Future studies should use validated patient reported outcome measures with endpoints that represent a predefi ned clinically meaningful change in symptom scores.